Scientists at Oxford University claim to have developed the first malaria vaccine Efficiency is greater than 75%According to a preliminary study published in the medical journal The Lancet on Friday, this level is the target level set by the World Health Organization (WHO).
The preliminary results of the “preprint” of this study (that is, external review by other scientific experts is still required) reflect that the formulation is called R21/Matrix-M, orProvides 77% efficacy in the next 12 months.
Vaccine display “Unprecedented level of efficiency” According to Halidou Tinto, Regional Director of the Nanoro Clinical Research Department in the central region of the country, the study was carried out in Burkina Faso from May to early August 2019, with 450 people from 5 to 17 Months old are developing in the area.
In the words of scientists, after these initial “very exciting” results, Several African countries will host a new experimental phase, 4800 children between 5 and 36 months of age confirmed this finding. The WHO estimates that malaria causes more than 400,000 deaths worldwide each year, most of which are African children, and pointed out that in 2019 alone, 229 million cases were reported.
In recent decades, more than 100 candidate malaria vaccines have entered clinical trials, but So far, no drug has an efficacy greater than 75% As envisaged in the WHO Technical Roadmap for Malaria Vaccines.
The preparations for the Jenner Institute related to the University of Oxford have been completed Together with the pharmaceutical company Serum Institute of India (SII) and Novavax in the United States.
Adrian Hill, director of the Jenner Institute and co-author of the study, said in a statement: “If licensed, the vaccine could have a significant impact on public health.” According to experts, If the vaccine is approved, at least 200 million doses will be distributed every yearFor several years.